Omecamtiv mecarbil shows trend toward reduced serious arrhythmia risk in HFrEF post hoc analysis

This is a post hoc analysis of a randomized controlled trial. The study population included 8232 participants with symptomatic chronic heart failure and left ventricular ejection fraction of 35 percent or less. The intervention was omecamtiv mecarbil, and the comparator was placebo. The median follow-up was 21.8 months. The primary outcome was a composite of the first occurrence of serious ventricular arrhythmia, cardiac arrest, or sudden death.

The main result for the primary outcome showed a trend towards reduced risk with omecamtiv mecarbil. The hazard ratio was 0.86, with a 95 percent confidence interval of 0.75 to 1.00 and a P value of .054. There were 377 events in the placebo group versus 329 in the omecamtiv mecarbil study arm. In a prespecified subgroup of participants with left ventricular ejection fraction of 28 percent or less, the association between omecamtiv mecarbil and lower risk was stronger. The hazard ratio for this subgroup was 0.77, with a 95 percent confidence interval of 0.63 to 0.94 and a P value of .009. Absolute event numbers for this subgroup were not reported.

Key secondary outcomes included ventricular arrhythmias, cardiac arrest, and sudden death. These outcomes were components of the primary composite. The safety analysis noted that ventricular arrhythmias and cardiac arrest were investigator-reported adverse events. The serious adverse events were defined as serious ventricular arrhythmia, cardiac arrest, or sudden death. Data on treatment discontinuations and overall tolerability were not reported.

These results can be compared to prior landmark studies in heart failure with reduced ejection fraction. The main trial from which this post hoc analysis was derived showed no significant benefit for the primary heart failure outcome. The current analysis focuses on arrhythmic events, which were not the primary endpoint of the original trial. The findings are consistent with a potential protective effect on arrhythmia risk but remain exploratory.

Key methodological limitations include the post hoc nature of the analysis, which increases the risk of type I error and limits causal inference. The findings require prospective validation in the ongoing COMET-HF trial. The study setting was not reported, and funding or conflicts of interest were not reported. The certainty of the evidence is low due to the post hoc design.

Clinical implications are limited. The results suggest a possible reduction in serious arrhythmic events but do not establish causality. Practice decisions should not be altered based on this analysis. The trend towards reduced risk with a P value of .054 is not statistically significant by conventional thresholds.

Questions remain unanswered. Prospective validation is needed to confirm whether omecamtiv mecarbil reduces serious arrhythmic events in heart failure with reduced ejection fraction. The optimal patient subgroup, such as those with very low ejection fraction, requires further study. The mechanisms underlying the observed trend are not elucidated.